Climb Bio, Inc.
CLYM evidence brief
What we can confirm
- BioSniper Score:
- 5.8 / 10
- Market Cap:
- $824.8M
- Lead Asset:
- budoprutug (Phase 2)
What it means
What to watch
Prepared research question
What matters most for CLYM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CLYM
Climb Bio, Inc. (CLYM) is a clinical-stage biotechnology company developing monoclonal antibody therapeutics for immune-mediated diseases, with lead programs budoprutug (targeting CD20 for pMN, ITP, SLE) and CLYM116 (targeting APRIL for IgA nephropathy).
Key risk: No approved products
BioSniper Score
Based on 5 of 6 signals
Market Cap
$824.8M
Cash Runway
—
Lead Asset
budoprutug (Phase 2)
Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 6 clinical trials · 1 catalyst for Climb Bio, Inc..
Climb Bio, Inc. (CLYM) is a clinical-stage biotechnology company developing monoclonal antibody therapeutics for immune-mediated diseases, with lead programs budoprutug (targeting CD20 for pMN, ITP, SLE) and CLYM116 (targeting APRIL for IgA nephropathy).
- Cash & equivalents of $44.1M as of 2026-06-30 [sec].
- Net loss of $13.5M for the period ending 2026-06-30 [sec].
- Shareholders' equity of $239.5M as of 2026-06-30 [sec].
- Lead programs: budoprutug (anti-CD20) for pMN, ITP, SLE; CLYM116 (anti-APRIL) for IgAN [sec_mda].
- Phase 2 topline data for budoprutug in pMN expected by 2026-12-31 [catalyst].
What works
- Two distinct immunology assets (budoprutug and CLYM116) targeting multiple immune-mediated diseases, providing pipeline diversification [sec_mda].
- CLYM116 is a next-generation anti-APRIL mAb with potent blocking of APRIL signaling, supported by positive Phase 1 data and planned Phase 2 initiation in IgAN [sec_mda].
- Subcutaneous formulation of budoprutug showed robust B-cell depletion similar to IV formulation, supporting advancement to multiple-dose studies [sec_mda].
What to weigh
- No approved products; company relies on external funding and faces typical biotech development risks [sec_mda].
- Forward-looking statements caution that actual results may differ materially from expectations due to numerous risks including regulatory, clinical, and competitive factors [sec].
- Cash position of $44.1M may be limited relative to the costs of multiple ongoing and planned clinical programs [sec].
- Clinical data from early-stage trials may not replicate in later-stage studies [sec].
From the filings
Quoted directly from source documents.
CLYM116 is a next generation anti-APRIL mAb for IgAN
“CLYM116, a next generation anti-APRIL (A PRoliferation-Inducing Ligand) mAb for the treatment of patients with immunoglobulin A nephropathy (IgAN) and other B-cell mediated diseases.”
SEC MD&A · August 6, 2026
Subcutaneous budoprutug formulation showed robust B-cell depletion
“The SC formulation of budoprutug was generally well-tolerated and resulted in robust B-cell depletion, which was similar to the IV formulation at a matched dose.”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline — Topline data from Phase 2 study of budoprutug in primary membranous nephropathy (pMN) expected; will inform advancement and expansion decisions.
Risks & what to watch (4)›
Key risks
- No approved products — Company has no marketed products and relies on external funding; all programs are in clinical or preclinical stages [sec_mda].
- Clinical trial risks — Positive early results may not replicate in later trials; regulatory approvals are uncertain [sec].
- Competitive landscape — Faces competition from other companies developing treatments for pMN, ITP, SLE, IgAN [sec].
- Cash runway constraints — Cash of $44.1M may be insufficient to fund all planned programs without additional financing [sec].
What to watch
- Phase 2 topline data for budoprutug in pMN expected by 2026-12-31 [catalyst].
- Initial data from SC formulation multiple-dose study expected in 2027 [sec_mda].
- Phase 1 data updates for CLYM116 at R&D Spotlight on September 3, 2026 [sec_mda].
- First IgAN patient dosing in Phase 2 by Mabworks in Q3 2026 [sec_mda].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 14, 2026 · How we verify sources →
Run Climb Bio, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Climb Bio, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.03 · 0% dilution
Lead: Phase 2
2 candidates
1 upcoming, next in ~78d
0 buys · 1 sell (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
80
Total value held
$207.8M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 11,300,939 | $77.4M |
| mpm bioimpact llc | 2,593,439 | $17.8M |
| braidwell lp | 1,529,675 | $10.5M |
| great point partners llc | 1,334,130 | $9.1M |
| millennium management llc | 1,276,260 | $8.7M |
| vanguard capital management llc | 1,178,659 | $8.1M |
| kynam capital management, lp | 1,003,341 | $6.9M |
| marshall wace, llp | 773,123 | $5.3M |
| affinity asset advisors, llc | 700,000 | $4.8M |
| silverarc capital management, llc | 684,908 | $4.7M |
Showing top 10 of 80 institutional holders of Climb Bio, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 4.4%
- Days to cover
- 2.6
- Shares short
- 1,776,821
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CLYM short interestGovernance
Frequently asked questions
What is the AI investment thesis for Climb Bio, Inc.?
Climb Bio, Inc. (CLYM) is a clinical-stage biotechnology company developing monoclonal antibody therapeutics for immune-mediated diseases, with lead programs budoprutug (targeting CD20 for pMN, ITP, SLE) and CLYM116 (targeting APRIL for IgA nephropathy).
What is Climb Bio, Inc.'s lead drug candidate?
Climb Bio, Inc.'s most advanced tracked candidate is budoprutug (Phase 2) for Immune Thrombocytopenia (ITP); Systemic Lupus Erthematosus; Healthy Volunteers.
What is Climb Bio, Inc.'s next catalyst?
Climb Bio, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase2_Topline: Climb Bio: 'Buy' On Budoprutug Phase 2 Advancement pMN And Expansions Underway" — expected December 31, 2026.
Who is the CEO of Climb Bio, Inc.?
Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc is the chief executive officer of Climb Bio, Inc. (CLYM).
Where is Climb Bio, Inc. headquartered?
Climb Bio, Inc. (CLYM) is headquartered in Wellesley Hills, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.